

*Abstract #CT07 Co-Authors:* Vania T.M. Hungria, Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil; Hans C. Lee, Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Rafat Abonour, Hematology/Oncology, Indiana University School of Medicine, Indianapolis; Robert M. Rifkin, Rocky Mountain Cancer Center and US Oncology Research, Denver, CO; Evangelos Terpos, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Xavier Leleu, Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, France; Caitlin L. Costello, Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla; Frits van Rhee, UAMS Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR; Katja C. Weisel, Department of Oncology, Hematology, Stem Cell Transplantation with Section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany; Noemi Puig, Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain; Gordon Cook, Department of Haematology, Clinical Trials Research Unit, NIHR (Leeds) IVD Cooperative, Leeds Teaching Hospital, Leeds, UK; Saad Z. Usmani, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC; Michael A. Thompson, Aurora Cancer Care, Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI; Mario Boccadoro, Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Italy; Jeffrey A. Zonder, Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI; Andrew Spencer, Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia; Roman Hajek, Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; Suzanne R. Fanning, Prisma Health–Upstate, Greenville, SC; Kevin D. Boyd, Division of Haematology, The Royal Marsden NHS Foundation Trust, London, UK; Jim Omel, Central Nebraska Myeloma Support Group, Grand Island, NE; Mira Armour, Mijelom CRO, Croatian Myeloma Support Association, Zagreb, Croatia; Kathryn E. Morgan, Myeloma Patients Europe, Brussels, Belgium; Ronak S. Patel, former Takeda Post-PharmD Fellow, Cambridge, MA; Renda H. Ferrari, Millennium Pharmaceuticals; Dawn Marie Stull, Millennium Pharmaceuticals; Kaili Ren, Millennium Pharmaceuticals; Dasha Cherepanov, Millennium Pharmaceuticals; James V. Pottala, Biostatistics, PPD, Wilmington, NC; Ajai Chari, Department of Hematology-Oncology, Mount Sinai School of Medicine, New York, NY; Jesus G. Berdeja, Department of Hematology, Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN